Newron’s shares dive after rare disease drug failureNewron’s share price has collapsed after the biotech axed development of its drug sarizotan for the rare genetic brain disorder Rett Syndrome following the failure of a key trial. Share XNewron’s shares dive after rare disease drug failurehttps://pharmaphorum.com/news/newrons-shares-dive-after-rare-disease-drug-failure/
